<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02873338</url>
  </required_header>
  <id_info>
    <org_study_id>CNTX-CX-01-2015-AML-1</org_study_id>
    <nct_id>NCT02873338</nct_id>
  </id_info>
  <brief_title>Randomized Study of CX-01 Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia</brief_title>
  <official_title>A Randomized, Phase II Study of CX-01 Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chimerix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chimerix</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was an exploratory Phase 2, open label, randomized, multicenter , parallel group study&#xD;
      to determine whether there was evidence that the addition of dociparstat (CX-01) at 2&#xD;
      different does levels to standard induction therapy (cytarabine+idarubicin, &quot;7+3&quot;) and&#xD;
      consolidation therapy had an additive therapeutic effect for subjects newly diagnosed with&#xD;
      acute myeloid leukemia (AML) when compared with subjects receiving standard induction&#xD;
      chemotherapy alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was an exploratory Phase 2, open label, randomized, multicenter , parallel group study&#xD;
      to determine whether there was evidence that the addition of dociparstat (CX-01) at 2&#xD;
      different does levels to standard induction therapy (cytarabine+idarubicin, &quot;7+3&quot;) and&#xD;
      consolidation therapy had an additive therapeutic effect for subjects newly diagnosed with&#xD;
      acute myeloid leukemia (AML) when compared with subjects receiving standard induction&#xD;
      chemotherapy alone.&#xD;
&#xD;
      Approximately 75 subjects were to be randomized in a 1:1:1 ratio to 1 of the following&#xD;
      treatment groups:&#xD;
&#xD;
        -  Group 1: cytarabine+idarubicin&#xD;
&#xD;
        -  Group 2: cytarabine+idarubicin + dociparstat 0.125 mg/kg/h&#xD;
&#xD;
        -  Group 3: cytarabine+idarubicin + dociparstat 0.25 mg/kg/h&#xD;
&#xD;
      Subjects received up to 2 induction cycles and up to 2 consolidation cycles and participated&#xD;
      in the study for up to 18 months. Clinical laboratory tests were conducted routinely, and&#xD;
      bone marrow aspirates and biopsies were performed during the induction cycles. Safety was&#xD;
      monitored through adverse events and clinical laboratory results.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Actual">June 2019</completion_date>
  <primary_completion_date type="Actual">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Who Achieved Morphologic Complete Remission</measure>
    <time_frame>during induction and re-induction phases of treatment (up to 60 days after the start of each treatment cycle)</time_frame>
    <description>Morphologic complete remission (CR) was evaluated by IWG criteria and defined as ANC &gt;1000/microliter; platelet count &gt;100,000, &lt;5% blasts in bone marrow aspirate, no blasts with Auer rods, and no evidence of extramedullary disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Event-free Survival</measure>
    <time_frame>randomization through treatment failure</time_frame>
    <description>Event-free survival was measured as time from randomization until treatment failure. Treatment failure was defined as failure to achieve composite completed morphological remission during the induction and re-induction phase of the study lasting up to 60 days, relapse from complete response, or death from any cause, whichever occurred first. Assessments were performed every 3 months and continued until death or 18 months after the last subject was randomized, whichever occurred first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Leukemia-free Survival</measure>
    <time_frame>Randomization until disease relapse or death from any cause, whichever occurred first.</time_frame>
    <description>Leukemia-free survival was assessed as a secondary endpoint only in subjects who achieved composite complete remission and was measured from randomization until disease relapse or death from any cause, whichever occurred first. Assessments were performed every 3 months until death or 18 months after the last subject was randomized, whichever occurred first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Achieved Overall Survival</measure>
    <time_frame>Randomization until death or 18 months after the last patient was randomized, whichever occurred first.</time_frame>
    <description>Overall survival was measured from the date of randomization until death from any cause. Assessments were performed every 3 months and continued until death or 18 months after the last patient was randomized, whichever came first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Achieved Composite Complete Remission</measure>
    <time_frame>Up to 60 days after the start of each treatment cycle</time_frame>
    <description>The composite complete remission (CR) rate included CR, CR without recovery of platelets (CRp), and CR without recovery of neutrophils and/or platelets (CRi), as defined by the International Working Group criteria during the induction and re-induction phases of treatment. CR was defined as an Absolute Neutrophil Count (ANC) &gt;1000/μL, platelet count &gt;100,000/μL, &lt;5% blasts in bone marrow aspirate, no blasts with Auer rods, and no evidence of extramedullary disease. CRi was defined as an ANC &lt;1000/μL and/or platelet count &lt;100,000/, &lt;5% blasts in bone marrow aspirate, no blasts with Auer rods, and no evidence of extramedullary disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Morphologic Complete Remission</measure>
    <time_frame>Randomization until death or 18 months after the last patient was randomized, whichever occurred first.</time_frame>
    <description>The duration of morphologic complete remission was assessed only in subjects who had achieved morphologic complete remission and was defined as the time from achievement of complete response to the detection or relapse. Relapse was defined as the reappearance of leukemia blasts in the peripheral blood, &gt;5% blasts in the bone marrow not attributable to another cause, or appearance/reappearance of extramedullary disease and with a bone marrow blast percentage of &gt;5% but ≤20%. If the latter, a repeat bone marrow examination was performed at least 7 days after the first marrow examination; documentation of the bone marrow blast percentage of &gt;5% was necessary to establish relapse. Assessments were performed every 3 months and continued until death or 18 months after the last subject was randomized, whichever occurred first.&#xD;
Duration of morphologic complete remission (time from the achievement of complete response to the detection of relapse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Recovery of Neutrophils</measure>
    <time_frame>Randomization to ANC recovery, for up to 60 days after the start of each treatment cycle</time_frame>
    <description>Neutrophil recovery was assessed from randomization to Absolute Neutrophil Count (ANC) recovery (ANC &gt;500/µL and &gt;1000/µL) for up to 60 days after the start of each treatment cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Platelet Recovery</measure>
    <time_frame>Randomization to platelet recovery, for up to 60 days after the start of each treatment cycle</time_frame>
    <description>Platelet recovery was measured from randomization to platelet recovery (platelet count &gt;20,000/µL and &gt;100,000/µL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Died by Day 30</measure>
    <time_frame>30 days (from first day of induction treatment to 30 days after)</time_frame>
    <description>Mortality (rate of death) of subjects by Day 30, measured from the first day of induction treatment to 30 days post-induction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Died by Day 60.</measure>
    <time_frame>60 days (from the first day of induction treatment to 60 days after)</time_frame>
    <description>Mortality (rate of death) of subjects by Day 60, measured from the first day of induction treatment to 60 days post-induction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Died by Day 90</measure>
    <time_frame>90 days (from the first day of induction treatment to 90 days after)</time_frame>
    <description>Mortality (rate of death) of subjects at Day 90, measured from the first day of induction treatment to 90 days post-induction.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Control (idarubicin+cytarabine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction:&#xD;
Idarubicin 12 mg/m2/day by slow (10 to 30 minutes) intravenous (IV) injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Idarubicin 12 mg/m2/day slow (10 to 30 minutes) IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hour IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
• Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dociparstat 0.125 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-7)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-5)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion on (Days 1-5; total 120 hours)&#xD;
Cytarabine 1.0 g/m2 over 3 hrs, every 12 hrs (Days 1, 3, 5)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dociparstat 0.25 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-7)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Dociparstat 4 mg/kg initial bolus 20 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5; total 120 hours)&#xD;
Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CX-01</intervention_name>
    <description>4 mg/kg IV bolus followed by doses of 0.125, or 0.25 mg/kg/hr given on days 1 through 7 with standard induction therapy, on days 1 through 5 or 7 with standard re-induction therapy, and on days 1, 3 and 5 with standard consolidation therapy</description>
    <arm_group_label>Dociparstat 0.125 mg/kg</arm_group_label>
    <arm_group_label>Dociparstat 0.25 mg/kg</arm_group_label>
    <other_name>2-O, 3-O desulfated heparin</other_name>
    <other_name>ODSH</other_name>
    <other_name>PGX-100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
    <description>12 mg/m2/day by slow (10 to 15 minutes) IV injection daily on days 1, 2 and 3 of induction therapy, and on days 1 and 2 of re-induction therapy</description>
    <arm_group_label>Control (idarubicin+cytarabine)</arm_group_label>
    <arm_group_label>Dociparstat 0.125 mg/kg</arm_group_label>
    <arm_group_label>Dociparstat 0.25 mg/kg</arm_group_label>
    <other_name>Idamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>100 mg/m2/day by continuous IV infusion on days 1 through 7 of induction therapy, and on days 1 through 5 of re-induction therapy&#xD;
1.0 g/m2 IV infusion given over 3 hours every 12 hours on days 1, 3, and 5 of consolidation therapy</description>
    <arm_group_label>Control (idarubicin+cytarabine)</arm_group_label>
    <arm_group_label>Dociparstat 0.125 mg/kg</arm_group_label>
    <arm_group_label>Dociparstat 0.25 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed, de novo or secondary, previously untreated AML&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute promyelocytic leukemia&#xD;
&#xD;
          -  Prior chemotherapy for AML&#xD;
&#xD;
          -  Prior intensive chemotherapy or stem cell transplantation for the treatment of&#xD;
             myelodysplastic syndrome&#xD;
&#xD;
          -  CNS leukemia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Marcus, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cantex Pharmaceuticals. Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Diego, Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franciscan St. Francis Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>June E. Nylen Cancer Center</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University/Tulane Cancer Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allina Health - Virginia Piper Cancer Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Mexico Cancer Care Alliance</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health, Monter Cancer Center</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avera Cancer Institute</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology/Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute/Baylor Sammons Cancer Center/Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Healthcare System of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LDS Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 12, 2016</study_first_submitted>
  <study_first_submitted_qc>August 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2016</study_first_posted>
  <results_first_submitted>September 30, 2021</results_first_submitted>
  <results_first_submitted_qc>September 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 29, 2021</results_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT02873338/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT02873338/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control (Idarubicin+Cytarabine)</title>
          <description>Induction:&#xD;
Idarubicin 12 mg/m2/day by slow (10 to 30 minutes) intravenous (IV) injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Idarubicin 12 mg/m2/day slow (10 to 30 minutes) IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hour IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
• Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)</description>
        </group>
        <group group_id="P2">
          <title>Dociparstat 0.125 mg/kg</title>
          <description>Induction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-7)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-5)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion on (Days 1-5; total 120 hours)&#xD;
Cytarabine 1.0 g/m2 over 3 hrs, every 12 hrs (Days 1, 3, 5)</description>
        </group>
        <group group_id="P3">
          <title>Dociparstat 0.25 mg/kg</title>
          <description>Induction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-7)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Dociparstat 4 mg/kg initial bolus 20 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5; total 120 hours)&#xD;
Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other or Missing</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control (Idarubicin+Cytarabine)</title>
          <description>Induction:&#xD;
Idarubicin 12 mg/m2/day by slow (10 to 30 minutes) intravenous (IV) injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Idarubicin 12 mg/m2/day slow (10 to 30 minutes) IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hour IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
• Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)</description>
        </group>
        <group group_id="B2">
          <title>Dociparstat 0.125 mg/kg</title>
          <description>Induction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-7)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-5)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion on (Days 1-5; total 120 hours)&#xD;
Cytarabine 1.0 g/m2 over 3 hrs, every 12 hrs (Days 1, 3, 5)</description>
        </group>
        <group group_id="B3">
          <title>Dociparstat 0.25 mg/kg</title>
          <description>Induction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-7)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Dociparstat 4 mg/kg initial bolus 20 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5; total 120 hours)&#xD;
Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" spread="3.6"/>
                    <measurement group_id="B2" value="67" spread="4.8"/>
                    <measurement group_id="B3" value="68" spread="4.3"/>
                    <measurement group_id="B4" value="67" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AML</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>De novo</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Secondary</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time since AML diagnosis</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.1" spread="1.19"/>
                    <measurement group_id="B2" value="1.2" spread="1.15"/>
                    <measurement group_id="B3" value="1.0" spread="0.75"/>
                    <measurement group_id="B4" value="1.1" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline blasts in bone marrow</title>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" spread="25.9"/>
                    <measurement group_id="B2" value="47" spread="22.3"/>
                    <measurement group_id="B3" value="46" spread="26.6"/>
                    <measurement group_id="B4" value="46" spread="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Achieved Morphologic Complete Remission</title>
        <description>Morphologic complete remission (CR) was evaluated by IWG criteria and defined as ANC &gt;1000/microliter; platelet count &gt;100,000, &lt;5% blasts in bone marrow aspirate, no blasts with Auer rods, and no evidence of extramedullary disease.</description>
        <time_frame>during induction and re-induction phases of treatment (up to 60 days after the start of each treatment cycle)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control (Idarubicin+Cytarabine)</title>
            <description>Induction:&#xD;
Idarubicin 12 mg/m2/day by slow (10 to 30 minutes) intravenous (IV) injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Idarubicin 12 mg/m2/day slow (10 to 30 minutes) IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hour IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
• Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)</description>
          </group>
          <group group_id="O2">
            <title>Dociparstat 0.125 mg/kg</title>
            <description>Induction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-7)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-5)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion on (Days 1-5; total 120 hours)&#xD;
Cytarabine 1.0 g/m2 over 3 hrs, every 12 hrs (Days 1, 3, 5)</description>
          </group>
          <group group_id="O3">
            <title>Dociparstat 0.25 mg/kg</title>
            <description>Induction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-7)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Dociparstat 4 mg/kg initial bolus 20 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5; total 120 hours)&#xD;
Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Achieved Morphologic Complete Remission</title>
          <description>Morphologic complete remission (CR) was evaluated by IWG criteria and defined as ANC &gt;1000/microliter; platelet count &gt;100,000, &lt;5% blasts in bone marrow aspirate, no blasts with Auer rods, and no evidence of extramedullary disease.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Event-free Survival</title>
        <description>Event-free survival was measured as time from randomization until treatment failure. Treatment failure was defined as failure to achieve composite completed morphological remission during the induction and re-induction phase of the study lasting up to 60 days, relapse from complete response, or death from any cause, whichever occurred first. Assessments were performed every 3 months and continued until death or 18 months after the last subject was randomized, whichever occurred first.</description>
        <time_frame>randomization through treatment failure</time_frame>
        <population>Note, in the Dociparstat 0.125 mg/kg group, fewer than half of the subjects achieved complete CR, and thus were assessed as having an event on Day 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Control (Idarubicin+Cytarabine)</title>
            <description>Induction:&#xD;
Idarubicin 12 mg/m2/day by slow (10 to 30 minutes) intravenous (IV) injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Idarubicin 12 mg/m2/day slow (10 to 30 minutes) IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hour IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
• Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)</description>
          </group>
          <group group_id="O2">
            <title>Dociparstat 0.125 mg/kg</title>
            <description>Induction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-7)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-5)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion on (Days 1-5; total 120 hours)&#xD;
Cytarabine 1.0 g/m2 over 3 hrs, every 12 hrs (Days 1, 3, 5)</description>
          </group>
          <group group_id="O3">
            <title>Dociparstat 0.25 mg/kg</title>
            <description>Induction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-7)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Dociparstat 4 mg/kg initial bolus 20 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5; total 120 hours)&#xD;
Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Event-free Survival</title>
          <description>Event-free survival was measured as time from randomization until treatment failure. Treatment failure was defined as failure to achieve composite completed morphological remission during the induction and re-induction phase of the study lasting up to 60 days, relapse from complete response, or death from any cause, whichever occurred first. Assessments were performed every 3 months and continued until death or 18 months after the last subject was randomized, whichever occurred first.</description>
          <population>Note, in the Dociparstat 0.125 mg/kg group, fewer than half of the subjects achieved complete CR, and thus were assessed as having an event on Day 1.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243.5" lower_limit="1" upper_limit="853"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="922"/>
                    <measurement group_id="O3" value="171.5" lower_limit="1" upper_limit="842"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Leukemia-free Survival</title>
        <description>Leukemia-free survival was assessed as a secondary endpoint only in subjects who achieved composite complete remission and was measured from randomization until disease relapse or death from any cause, whichever occurred first. Assessments were performed every 3 months until death or 18 months after the last subject was randomized, whichever occurred first.</description>
        <time_frame>Randomization until disease relapse or death from any cause, whichever occurred first.</time_frame>
        <population>This analysis only included subjects who achieved composite complete remission. The following number of subjects were censored in each treatment group:&#xD;
Control: 6/16 (37.5%) subjects&#xD;
Dociparstat 0.125 mg/kg: 4/9 (44.4%) subjects&#xD;
Dociparstat 0.25 mg/kg: 10/15 (66.7%) subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Control (Idarubicin+Cytarabine)</title>
            <description>Induction:&#xD;
Idarubicin 12 mg/m2/day by slow (10 to 30 minutes) intravenous (IV) injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Idarubicin 12 mg/m2/day slow (10 to 30 minutes) IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hour IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
• Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)</description>
          </group>
          <group group_id="O2">
            <title>Dociparstat 0.125 mg/kg</title>
            <description>Induction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-7)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-5)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion on (Days 1-5; total 120 hours)&#xD;
Cytarabine 1.0 g/m2 over 3 hrs, every 12 hrs (Days 1, 3, 5)</description>
          </group>
          <group group_id="O3">
            <title>Dociparstat 0.25 mg/kg</title>
            <description>Induction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-7)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Dociparstat 4 mg/kg initial bolus 20 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5; total 120 hours)&#xD;
Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Leukemia-free Survival</title>
          <description>Leukemia-free survival was assessed as a secondary endpoint only in subjects who achieved composite complete remission and was measured from randomization until disease relapse or death from any cause, whichever occurred first. Assessments were performed every 3 months until death or 18 months after the last subject was randomized, whichever occurred first.</description>
          <population>This analysis only included subjects who achieved composite complete remission. The following number of subjects were censored in each treatment group:&#xD;
Control: 6/16 (37.5%) subjects&#xD;
Dociparstat 0.125 mg/kg: 4/9 (44.4%) subjects&#xD;
Dociparstat 0.25 mg/kg: 10/15 (66.7%) subjects</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="292" lower_limit="1" upper_limit="581"/>
                    <measurement group_id="O2" value="448" lower_limit="26" upper_limit="494"/>
                    <measurement group_id="O3" value="166" lower_limit="1" upper_limit="315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Achieved Overall Survival</title>
        <description>Overall survival was measured from the date of randomization until death from any cause. Assessments were performed every 3 months and continued until death or 18 months after the last patient was randomized, whichever came first.</description>
        <time_frame>Randomization until death or 18 months after the last patient was randomized, whichever occurred first.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control (Idarubicin+Cytarabine)</title>
            <description>Induction:&#xD;
Idarubicin 12 mg/m2/day by slow (10 to 30 minutes) intravenous (IV) injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Idarubicin 12 mg/m2/day slow (10 to 30 minutes) IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hour IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
• Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)</description>
          </group>
          <group group_id="O2">
            <title>Dociparstat 0.125 mg/kg</title>
            <description>Induction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-7)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-5)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion on (Days 1-5; total 120 hours)&#xD;
Cytarabine 1.0 g/m2 over 3 hrs, every 12 hrs (Days 1, 3, 5)</description>
          </group>
          <group group_id="O3">
            <title>Dociparstat 0.25 mg/kg</title>
            <description>Induction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-7)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Dociparstat 4 mg/kg initial bolus 20 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5; total 120 hours)&#xD;
Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Achieved Overall Survival</title>
          <description>Overall survival was measured from the date of randomization until death from any cause. Assessments were performed every 3 months and continued until death or 18 months after the last patient was randomized, whichever came first.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Subjects died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Subjects still alive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Achieved Composite Complete Remission</title>
        <description>The composite complete remission (CR) rate included CR, CR without recovery of platelets (CRp), and CR without recovery of neutrophils and/or platelets (CRi), as defined by the International Working Group criteria during the induction and re-induction phases of treatment. CR was defined as an Absolute Neutrophil Count (ANC) &gt;1000/μL, platelet count &gt;100,000/μL, &lt;5% blasts in bone marrow aspirate, no blasts with Auer rods, and no evidence of extramedullary disease. CRi was defined as an ANC &lt;1000/μL and/or platelet count &lt;100,000/, &lt;5% blasts in bone marrow aspirate, no blasts with Auer rods, and no evidence of extramedullary disease.</description>
        <time_frame>Up to 60 days after the start of each treatment cycle</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control (Idarubicin+Cytarabine)</title>
            <description>Induction:&#xD;
Idarubicin 12 mg/m2/day by slow (10 to 30 minutes) intravenous (IV) injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Idarubicin 12 mg/m2/day slow (10 to 30 minutes) IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hour IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
• Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)</description>
          </group>
          <group group_id="O2">
            <title>Dociparstat 0.125 mg/kg</title>
            <description>Induction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-7)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-5)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion on (Days 1-5; total 120 hours)&#xD;
Cytarabine 1.0 g/m2 over 3 hrs, every 12 hrs (Days 1, 3, 5)</description>
          </group>
          <group group_id="O3">
            <title>Dociparstat 0.25 mg/kg</title>
            <description>Induction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-7)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Dociparstat 4 mg/kg initial bolus 20 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5; total 120 hours)&#xD;
Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Achieved Composite Complete Remission</title>
          <description>The composite complete remission (CR) rate included CR, CR without recovery of platelets (CRp), and CR without recovery of neutrophils and/or platelets (CRi), as defined by the International Working Group criteria during the induction and re-induction phases of treatment. CR was defined as an Absolute Neutrophil Count (ANC) &gt;1000/μL, platelet count &gt;100,000/μL, &lt;5% blasts in bone marrow aspirate, no blasts with Auer rods, and no evidence of extramedullary disease. CRi was defined as an ANC &lt;1000/μL and/or platelet count &lt;100,000/, &lt;5% blasts in bone marrow aspirate, no blasts with Auer rods, and no evidence of extramedullary disease.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Morphologic Complete Remission</title>
        <description>The duration of morphologic complete remission was assessed only in subjects who had achieved morphologic complete remission and was defined as the time from achievement of complete response to the detection or relapse. Relapse was defined as the reappearance of leukemia blasts in the peripheral blood, &gt;5% blasts in the bone marrow not attributable to another cause, or appearance/reappearance of extramedullary disease and with a bone marrow blast percentage of &gt;5% but ≤20%. If the latter, a repeat bone marrow examination was performed at least 7 days after the first marrow examination; documentation of the bone marrow blast percentage of &gt;5% was necessary to establish relapse. Assessments were performed every 3 months and continued until death or 18 months after the last subject was randomized, whichever occurred first.&#xD;
Duration of morphologic complete remission (time from the achievement of complete response to the detection of relapse)</description>
        <time_frame>Randomization until death or 18 months after the last patient was randomized, whichever occurred first.</time_frame>
        <population>This analysis only included subjects who had achieved morphologic complete remission.&#xD;
The following number of subjects were censored in each treatment group for this analysis; however the full ranges include censored subjects:&#xD;
Control: 7/14 (50%) subjects&#xD;
Dociparstat 0.125 mg/kg: 6/8 (75.0%) subjects&#xD;
Dociparstat 0.25 mg/kg: 9/11 (81.8%) subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Control (Idarubicin+Cytarabine)</title>
            <description>Induction:&#xD;
Idarubicin 12 mg/m2/day by slow (10 to 30 minutes) intravenous (IV) injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Idarubicin 12 mg/m2/day slow (10 to 30 minutes) IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hour IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
• Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)</description>
          </group>
          <group group_id="O2">
            <title>Dociparstat 0.125 mg/kg</title>
            <description>Induction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-7)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-5)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion on (Days 1-5; total 120 hours)&#xD;
Cytarabine 1.0 g/m2 over 3 hrs, every 12 hrs (Days 1, 3, 5)</description>
          </group>
          <group group_id="O3">
            <title>Dociparstat 0.25 mg/kg</title>
            <description>Induction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-7)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Dociparstat 4 mg/kg initial bolus 20 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5; total 120 hours)&#xD;
Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Morphologic Complete Remission</title>
          <description>The duration of morphologic complete remission was assessed only in subjects who had achieved morphologic complete remission and was defined as the time from achievement of complete response to the detection or relapse. Relapse was defined as the reappearance of leukemia blasts in the peripheral blood, &gt;5% blasts in the bone marrow not attributable to another cause, or appearance/reappearance of extramedullary disease and with a bone marrow blast percentage of &gt;5% but ≤20%. If the latter, a repeat bone marrow examination was performed at least 7 days after the first marrow examination; documentation of the bone marrow blast percentage of &gt;5% was necessary to establish relapse. Assessments were performed every 3 months and continued until death or 18 months after the last subject was randomized, whichever occurred first.&#xD;
Duration of morphologic complete remission (time from the achievement of complete response to the detection of relapse)</description>
          <population>This analysis only included subjects who had achieved morphologic complete remission.&#xD;
The following number of subjects were censored in each treatment group for this analysis; however the full ranges include censored subjects:&#xD;
Control: 7/14 (50%) subjects&#xD;
Dociparstat 0.125 mg/kg: 6/8 (75.0%) subjects&#xD;
Dociparstat 0.25 mg/kg: 9/11 (81.8%) subjects</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233" lower_limit="1" upper_limit="451"/>
                    <measurement group_id="O2" value="494" lower_limit="1" upper_limit="494"/>
                    <measurement group_id="O3" value="294" lower_limit="1" upper_limit="315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Recovery of Neutrophils</title>
        <description>Neutrophil recovery was assessed from randomization to Absolute Neutrophil Count (ANC) recovery (ANC &gt;500/µL and &gt;1000/µL) for up to 60 days after the start of each treatment cycle.</description>
        <time_frame>Randomization to ANC recovery, for up to 60 days after the start of each treatment cycle</time_frame>
        <population>The following number of subjects were censored in each treatment group for both analyses (neutrophil recovery to &gt;500/µL and &gt;1000/µL):&#xD;
Control: 6/26 (23.1%) subjects for both analyses (&gt;500/µL and &gt;1000/µL)&#xD;
Dociparstat 0.125 mg/kg: 9/25 (36.0%) subjects for both analyses (&gt;500/µL and &gt;1000/µL)&#xD;
Dociparstat 0.25 mg/kg: 7/24 (29.2%) subjects for &gt;500/µL and 11/24 (45.8%) subjects for &gt;1000/µL</population>
        <group_list>
          <group group_id="O1">
            <title>Control (Idarubicin+Cytarabine)</title>
            <description>Induction:&#xD;
Idarubicin 12 mg/m2/day by slow (10 to 30 minutes) intravenous (IV) injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Idarubicin 12 mg/m2/day slow (10 to 30 minutes) IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hour IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
• Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)</description>
          </group>
          <group group_id="O2">
            <title>Dociparstat 0.125 mg/kg</title>
            <description>Induction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-7)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-5)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion on (Days 1-5; total 120 hours)&#xD;
Cytarabine 1.0 g/m2 over 3 hrs, every 12 hrs (Days 1, 3, 5)</description>
          </group>
          <group group_id="O3">
            <title>Dociparstat 0.25 mg/kg</title>
            <description>Induction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-7)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Dociparstat 4 mg/kg initial bolus 20 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5; total 120 hours)&#xD;
Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Recovery of Neutrophils</title>
          <description>Neutrophil recovery was assessed from randomization to Absolute Neutrophil Count (ANC) recovery (ANC &gt;500/µL and &gt;1000/µL) for up to 60 days after the start of each treatment cycle.</description>
          <population>The following number of subjects were censored in each treatment group for both analyses (neutrophil recovery to &gt;500/µL and &gt;1000/µL):&#xD;
Control: 6/26 (23.1%) subjects for both analyses (&gt;500/µL and &gt;1000/µL)&#xD;
Dociparstat 0.125 mg/kg: 9/25 (36.0%) subjects for both analyses (&gt;500/µL and &gt;1000/µL)&#xD;
Dociparstat 0.25 mg/kg: 7/24 (29.2%) subjects for &gt;500/µL and 11/24 (45.8%) subjects for &gt;1000/µL</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Recovery to &gt;500/µL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="1" upper_limit="57"/>
                    <measurement group_id="O2" value="43" lower_limit="9" upper_limit="70"/>
                    <measurement group_id="O3" value="29" lower_limit="1" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recovery to &gt;1000/µL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" lower_limit="1" upper_limit="64"/>
                    <measurement group_id="O2" value="42" lower_limit="9" upper_limit="70"/>
                    <measurement group_id="O3" value="35" lower_limit="1" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Platelet Recovery</title>
        <description>Platelet recovery was measured from randomization to platelet recovery (platelet count &gt;20,000/µL and &gt;100,000/µL)</description>
        <time_frame>Randomization to platelet recovery, for up to 60 days after the start of each treatment cycle</time_frame>
        <population>The following number of subjects were censored in each treatment group for each analysis (platelet recovery to &gt;20,000µL and &gt;100,000µL):&#xD;
Control: 5/26 (19.2%) subjects for &gt;20,000µL and 7/26 (26.9%) subjects for &gt;100,000µL&#xD;
Dociparstat 0.125 mg/kg: 5/25 (20%) subjects for &gt;20,000µL and 12/25 (48.0%) subjects for &gt;100,000µL&#xD;
Dociparstat 0.25 mg/kg: 8/24 (33.3%) subjects for &gt;20,000µL and 11/24 (45.8%) subjects for &gt;100,000µL</population>
        <group_list>
          <group group_id="O1">
            <title>Control (Idarubicin+Cytarabine)</title>
            <description>Induction:&#xD;
Idarubicin 12 mg/m2/day by slow (10 to 30 minutes) intravenous (IV) injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Idarubicin 12 mg/m2/day slow (10 to 30 minutes) IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hour IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
• Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)</description>
          </group>
          <group group_id="O2">
            <title>Dociparstat 0.125 mg/kg</title>
            <description>Induction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-7)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-5)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion on (Days 1-5; total 120 hours)&#xD;
Cytarabine 1.0 g/m2 over 3 hrs, every 12 hrs (Days 1, 3, 5)</description>
          </group>
          <group group_id="O3">
            <title>Dociparstat 0.25 mg/kg</title>
            <description>Induction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-7)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Dociparstat 4 mg/kg initial bolus 20 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5; total 120 hours)&#xD;
Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Platelet Recovery</title>
          <description>Platelet recovery was measured from randomization to platelet recovery (platelet count &gt;20,000/µL and &gt;100,000/µL)</description>
          <population>The following number of subjects were censored in each treatment group for each analysis (platelet recovery to &gt;20,000µL and &gt;100,000µL):&#xD;
Control: 5/26 (19.2%) subjects for &gt;20,000µL and 7/26 (26.9%) subjects for &gt;100,000µL&#xD;
Dociparstat 0.125 mg/kg: 5/25 (20%) subjects for &gt;20,000µL and 12/25 (48.0%) subjects for &gt;100,000µL&#xD;
Dociparstat 0.25 mg/kg: 8/24 (33.3%) subjects for &gt;20,000µL and 11/24 (45.8%) subjects for &gt;100,000µL</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Recovery to &gt;20,000µL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="1" upper_limit="71"/>
                    <measurement group_id="O2" value="36" lower_limit="16" upper_limit="70"/>
                    <measurement group_id="O3" value="29" lower_limit="1" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recovery to &gt;100,000µL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" lower_limit="1" upper_limit="71"/>
                    <measurement group_id="O2" value="50" lower_limit="16" upper_limit="70"/>
                    <measurement group_id="O3" value="32" lower_limit="1" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Died by Day 30</title>
        <description>Mortality (rate of death) of subjects by Day 30, measured from the first day of induction treatment to 30 days post-induction.</description>
        <time_frame>30 days (from first day of induction treatment to 30 days after)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control (Idarubicin+Cytarabine)</title>
            <description>Induction:&#xD;
Idarubicin 12 mg/m2/day by slow (10 to 30 minutes) intravenous (IV) injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Idarubicin 12 mg/m2/day slow (10 to 30 minutes) IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hour IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
• Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)</description>
          </group>
          <group group_id="O2">
            <title>Dociparstat 0.125 mg/kg</title>
            <description>Induction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-7)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-5)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion on (Days 1-5; total 120 hours)&#xD;
Cytarabine 1.0 g/m2 over 3 hrs, every 12 hrs (Days 1, 3, 5)</description>
          </group>
          <group group_id="O3">
            <title>Dociparstat 0.25 mg/kg</title>
            <description>Induction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-7)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Dociparstat 4 mg/kg initial bolus 20 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5; total 120 hours)&#xD;
Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Died by Day 30</title>
          <description>Mortality (rate of death) of subjects by Day 30, measured from the first day of induction treatment to 30 days post-induction.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Died by Day 60.</title>
        <description>Mortality (rate of death) of subjects by Day 60, measured from the first day of induction treatment to 60 days post-induction.</description>
        <time_frame>60 days (from the first day of induction treatment to 60 days after)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control (Idarubicin+Cytarabine)</title>
            <description>Induction:&#xD;
Idarubicin 12 mg/m2/day by slow (10 to 30 minutes) intravenous (IV) injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Idarubicin 12 mg/m2/day slow (10 to 30 minutes) IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hour IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
• Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)</description>
          </group>
          <group group_id="O2">
            <title>Dociparstat 0.125 mg/kg</title>
            <description>Induction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-7)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-5)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion on (Days 1-5; total 120 hours)&#xD;
Cytarabine 1.0 g/m2 over 3 hrs, every 12 hrs (Days 1, 3, 5)</description>
          </group>
          <group group_id="O3">
            <title>Dociparstat 0.25 mg/kg</title>
            <description>Induction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-7)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Dociparstat 4 mg/kg initial bolus 20 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5; total 120 hours)&#xD;
Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Died by Day 60.</title>
          <description>Mortality (rate of death) of subjects by Day 60, measured from the first day of induction treatment to 60 days post-induction.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Died by Day 90</title>
        <description>Mortality (rate of death) of subjects at Day 90, measured from the first day of induction treatment to 90 days post-induction.</description>
        <time_frame>90 days (from the first day of induction treatment to 90 days after)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control (Idarubicin+Cytarabine)</title>
            <description>Induction:&#xD;
Idarubicin 12 mg/m2/day by slow (10 to 30 minutes) intravenous (IV) injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Idarubicin 12 mg/m2/day slow (10 to 30 minutes) IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hour IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
• Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)</description>
          </group>
          <group group_id="O2">
            <title>Dociparstat 0.125 mg/kg</title>
            <description>Induction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-7)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-5)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion on (Days 1-5; total 120 hours)&#xD;
Cytarabine 1.0 g/m2 over 3 hrs, every 12 hrs (Days 1, 3, 5)</description>
          </group>
          <group group_id="O3">
            <title>Dociparstat 0.25 mg/kg</title>
            <description>Induction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-7)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Dociparstat 4 mg/kg initial bolus 20 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5; total 120 hours)&#xD;
Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Died by Day 90</title>
          <description>Mortality (rate of death) of subjects at Day 90, measured from the first day of induction treatment to 90 days post-induction.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the date and time of first dose of study treatment to 30 days after the last dose of treatment, or if the event start date was prior to the date of first dose of study treatment and the severity worsened on or after the date and time of the first dose of study treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control (Idarubicin+Cytarabine)</title>
          <description>Induction:&#xD;
Idarubicin 12 mg/m2/day by slow (10 to 30 minutes) intravenous (IV) injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Idarubicin 12 mg/m2/day slow (10 to 30 minutes) IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hour IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
• Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)</description>
        </group>
        <group group_id="E2">
          <title>Dociparstat 0.125 mg/kg</title>
          <description>Induction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-7)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-5)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion on (Days 1-5; total 120 hours)&#xD;
Cytarabine 1.0 g/m2 over 3 hrs, every 12 hrs (Days 1, 3, 5)</description>
        </group>
        <group group_id="E3">
          <title>Dociparstat 0.25 mg/kg</title>
          <description>Induction:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-7)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)&#xD;
Reinduction:&#xD;
Dociparstat 4 mg/kg initial bolus 20 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5)&#xD;
Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)&#xD;
Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)&#xD;
Consolidation:&#xD;
Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5; total 120 hours)&#xD;
Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Venoocclusive liver disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Tumor lysis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Chapped lips</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Localised oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Enterococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Transfusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>International normalised ration increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Alkalosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Rash follicular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Details of the Study and its results shall not be publicized or published in any form without prior consent of the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Chimerix, Inc.</organization>
      <phone>919-806-1074 ext 101</phone>
      <email>dmoore@chimerix.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

